Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TERTIO in unresectable hepatocellular carcinoma
2022-500643-20-00Phase 2Authorised
- Sponsor
- CHU de Besançon
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in hepatocellular carcinoma (HCC) comparing UCPVax + atezolizumab + bevacizumab with Control: atezolizumab + bevacizumab (2 arms). Primary endpoint: Objective response rate at 6 months. Planned start Aug 2022; status: authorised.
02
Drugs
UCPVaxatezolizumabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2022-500643-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500643-20-00.